Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Hot Investor Mandate 4: Venture Arm of Large Korean Corporate Invests in Digital Health, with Increased Interests in Investment Opportunities in Biotech Therapeutics

3 May

A venture capital arm of a large Korean corporate has several offices in the USA. The firm has approximately has invested over $200M in 40 companies in the last year and invested $100M in 20 companies in 2016. The investment size greatly varies, depending on the opportunity. The firm is actively seeking new investment opportunities in the life sciences and will look globally.

The firm invests in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The firm is also interested in therapeutics, particularly synthetic biology, nanotechnology, and gene therapy. The firm is opportunistic in terms of stage of development.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Tags: , ,

RESI 2018 Investor Footprint

26 Apr

By Chris Cummings, Senior Marketing Manager, LSN

We are expecting significant international attendance at RESI Boston this June, due to its proximity to the BIO International Convention. Over 100 investors are already registered! The conference will be the third RESI of 2018, and is sure to continue matching early-stage investors with Biotech, Medtech, Diagnostics, and Digital Health startups. Check out some of the stats below to see what has happened so far at RESIs in 2018…


Click Here to See Investors

Tags: ,

RESI Boston Summer: Agenda Announced

26 Apr

By Lucy Parkinson, VP of Investor Research, LSN

BIO Week 2018 starts on June 4th, and it will be a busy time for all of us in the Boston life science scene.  RESI aims to kick off the week with a full day of partnering and focused content for early stage entrepreneurs who are looking for financing and strategic relationships.  RESI Boston Summer will feature new panels on Investment Opportunities in the Microbiome, Investing In Oncology Innovation, and Investing In Mental & Behavioral Health, as well as the return of RESI’s focused discussions on Family Offices, Venture Philanthropy, Big Pharma and many other topics that span the gamut of life science investment and technology.  With an international crowd heading to Boston for the busy conference week, the Asia-North America track will provide access to advice from experienced international delegates.  We hope you can join us on June 4th.

 

Tags:

Life Science Nation’s Redefining Early Stage Investments (RESI) Conference Series Changed the Game – Here’s How.

19 Apr

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation’s Redefining Early Stage Investments (RESI) conference series is unique in several ways:

  • The Innovation Challenge that takes place at every RESI conference is a huge hit with early stage global investors seeking firms that align with their investment mandates.  LSN developed an expert system that facilitates the quick scoring and ranking of all of the companies and their technology assets that apply to get into the Innovation Challenge. A typical RESI conference gets over 100+ applications and LSN vets and ranks the top 30 applicants.
  • RESI is held every few months at major innovation hubs and gives both fundraising CEOs, early-stage investor/partners and service providers a capability to use RESI as part of their ongoing yearly business and partnering activities. Scientist/entrepreneurs can weave themselves into the RESI conference series and dramatically increase face time with prime partnering targets. The ability to carry on a dialogue every few months greatly aids in transmitting the latest information and cultivating the relationships.
  • RESI is one of the very few healthcare conferences that is cross-domain, in that it features Biotech, Medtech, Diagnostics and Digital Health. Many investors have multiple investment mandates covering multiple silos in the life science arena.
  • RESI is primarily a powerful  partnering conference using a unique profile-based partnering system that will have up to 1400 meetings between buyers and sellers in one day. LSN has integrated a matching algorithm in our partnering software that connects the right investors/partners with the right early stage companies that are a fit for stage of development and product set. I think if you polled some of your colleagues they would say that RESI is a well-known partnering vehicle and attest to the dynamic nature of a RESI event.

The importance of continued dialog in maintaining partner relationships is specifically why LSN chose to incorporate a RESI conference every couple of months throughout the year.  RESI partnering has produced compelling results – over 350 firms have raised close to 500 million by using RESI as part of an ongoing fundraising vehicle.

LSN presently has 5 RESI conferences a year – JP Morgan (during), Toronto (part of Health Innovation Week), Summer BIO (day before), Boston (September) and NYC (November). The long-term goal is to expand RESI to China, Europe and South America and thus have a one-of-a-kind ongoing global event.

 

Mark Your Calendar: RESI Boston Summer on June 4th, 2018

12 Apr

By Samuel Rubin, Business Development Manager, LSN

Life Science Nation (LSN) and the RESI Conference now sets its sights on RESI Boston on June 4th, the day before the annual BIO Convention. This is the second year in a row LSN is holding a RESI Conference during BIO week, which promises to bring more than 15,000 life science executives to Boston. RESI specializes in early stage investor partnering, touting hundreds of qualified investment firms interested in meeting with innovative life science startups. No other Conference has such a deeply-rooted focus on early stage investment, complete with a robust data platform to connect with only those firms who are the right match. RESI will therefore offer significant value to folks traveling to BIO looking for something to do the Monday before BIO kicks off.

Registration is now open at the Early Bird Rate. If you would like to learn more about RESI Boston and why it’s a great choice for incorporating into your summer fundraising plans, don’t hesitate to contact us.

Click here to learn more about Premier Partnering Plus

Tags:

RESI Lands on MaRS in 5 Days – Check out the Program Guide

5 Apr

By Nono Hu, Director of Marketing, LSN

In 5 days, The Redefining Early Stage Investments (RESI) Conference will return to MaRS Discovery Centre, Toronto for the third time during the Toronto Health Innovation Week. So far, we have over 700 meetings booked through the RESI Partnering Platform, and have registered over 250 early stage investors.

If you’re planning your day at RESI on MaRS, check out the program guide now to find the full lineup of speakers, innovators, exhibitors and sponsors.

See you at MaRS on April 10th!

Tags: , , ,

Why MaRS Toronto for an International Early Stage Investor Conference?

5 Apr

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

There is a rich diversity of technology assets being developed in Toronto, as MaRS Discovery District and Johnson & Johnson’s JLABS have convened to create one of the most dynamic centers for life science technology innovation in North America. However, not to use an old cliché, Toronto’s real value in life science is in the people, from its visionary leaders to its extraordinary scientist-entrepreneurs, all striving (and succeeding) to move the needle and create the next generation of healthcare innovation.

When I first launched the Redefining Early Stage Investments (RESI) Conference in Toronto in 2016, my network of global early-stage investors were initially open to seeing what was up in the north country. Just two years and three Toronto RESI conferences later, I am witnessing unprecedented signups from the global investor community. Much to my amazement, this upcoming RESI conference (April 10th at MaRS Discovery Centre) has seen a 25% increase in investor and strategic partner registrations. We expect 300-350 qualified investors (all with vetted investment mandates) to peruse the lineup of hundreds of early-stage biotech, medtech, diagnostics and digital health startups. But one quite compelling factor is that we expect that almost 60% of the investors and partners will be from outside of Canada.

But I digress. Back to the people factor. What I learned from discussion with investors who have attended RESI on MaRS in the past was actually quite startling. The main takeaway from a majority of the investors I chatted with was that the caliber of the fundraising CEOs and scientist-entrepreneurs was the main differentiator. It was their genuineness and their lack of inflated value of their technology that impressed the investors. In contrast, the Boston, NYC and CA players had elevated expectations regarding the amount of time it takes to get a deal done, and the valuations of their assets were off the charts. The investors implied that if they find a deal they like in Toronto, the valuations and executive teams in Canada are much more realistic, which translates into getting contracts signed quicker. These perceptions impact and ignite the global investor community and have heightened interest in Toronto, which proves out the adage that if you build it, they will come!

 

Tags: , , ,

← Older Entries
Newer Entries →